Trial · NCT07134075
Intracochlear Injection of Glucocorticoid
NCT07134075, Phase 2, Not yet recruiting, Eye & ENT Hospital of Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intracochlear Injection of Glucocorticoid. Trials, record NCT07134075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07134075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intracochlear Injection of Glucocorticoid
- NCT number
- NCT07134075
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Eye & ENT Hospital of Fudan University
- Conditions
- Sudden Sensorineural Hearing Loss (SSNHL)
- Interventions
intracochlear triamcinolone acetonide injection, intracochlear injection of dexamethasone through the round window membrane, intracochlear dexamethasone injection and intratympanic dexamethasone injection, intratympanic dexamethasone injection
- First posted
- 2025-08-21
- Last updated
- 2025-08-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in pure tone audiometry (PTA) | Baseline, Week 2, Week 4, Week12, Week24 | hearing capacity of thresholds (PTA) |
| Primary | Change from Baseline in auditory brainstem response (ABR) | Baseline, Week 2, Week 4, Week12, Week24 | hearing capacity of thresholds (ABR) |
| Primary | Change from Baseline in auditory steady state response (ASSR) | Baseline, Week 2, Week 4, Week12, Week24 | hearing capacity of thresholds (ASSR) |
| Primary | Change from Baseline in speech Discrimination Scores | Baseline, Week 2, Week 4, Week12, Week24 | hearing capacity of thresholds (speech Discrimination Scores) |
| Secondary | change from baseline in tinnitus handicap inventory | Baseline, Week2, Week4, Week12, Week24 | The THI questionnaire includes functional, emotional, and catastrophic subscales. It consists of 25 questions. The total score is calculated by adding up the scores for all questions and classifying the severity of tinnitus as no handicap (0-16), mild handicap (18-36), moderate handicap (38-56), and severe handicap (58-100). |
| Secondary | change from baseline in dizziness handicap inventory | Baseline, Week2, Week4, Week12, Week24 | The 25-item self-report Dizziness Handicap inventory (DHI) validated questionnaire that assesses functional, emotional and physical domains. Responses are graded 0 (no), 2 (sometimes) or 4 (yes) with higher scores indicating greater impact of dizziness maximum and maximum score of 100 points (15 minutes). |
| Secondary | change from baseline in quality of life score | Baseline, Week2, Week4, Week12, Week24 | Quality of life questionnaire will be measured to compare the change in individual's health-related quality of life using face to face Interview for the scores. Higher scores mean better functioning or fewer symptoms. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07134075
GET https://conductscience.org/api/trials/v1/NCT07134075/registered